



RealRate

PHARMACEUTICAL 2019











PHARMACEUTICAL 2019



REGENERON PHARMACEUTICALS INC.



Rank 46 of 363

The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 112% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 201% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	6,447,600
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,442,800
Liabilities, Non-Current	825,900
Other Assets	2,711,100
Other Compr. Net Income	-6,300
Other Expenses	543,200
Other Liabilities	708,500
Other Net Income	19,100
Other Revenues	6,710,800
Property and Equipment	2,575,800
Research and Development	2,186,100
Selling, General and Administrative Expense	1,556,200

Output Variable	Value in 1000 USD
Assets	11,734,500
Liabilities	2,977,200
Expenses	4,285,500
Revenues	6,710,800
Stockholders Equity	8,757,300
Net Income	2,444,400
Comprehensive Net Income	2,441,250
Economic Capital Ratio	238%

